Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7981 to 7995 of 8975 results

  1. Ultroid 2.0 for internal haemorrhoids (MIB75)

    This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.

    Withdrawn advice

  2. VitalPAC for assessing vital signs of patients in hospital (MIB79)

    This advice has been updated and replaced by NICE medtech innovation briefing 205.

    Withdrawn advice

  3. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)

    This guidance has been updated and replaced by NICE's technology appraisal guidance 1129.

    Withdrawn guidance

  4. Insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure (IPG463)

    Interventional procedures, IPG463 - Issued: August 2013 --> This guidance has been updated and replaced by NICE HealthTech guidance 599.

    Withdrawn guidance

  5. Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus (IPG789)

    We have moved interventional procedures guidance 789 to become HealthTech guidance 723. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)

    This guidance has been updated and replaced by NICE technology appraisal guidance on dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134).

    Withdrawn guidance

  7. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    This guidance has been updated and replaced by NICE's highly specialised technologies guidance 34.

    Withdrawn guidance

  8. Kidney conditions: CKD and SGLT2 inhibitors (IND322)

    This indicator has been updated and replaced by NICE indicator 324.

    Withdrawn indicator

  9. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development Reference number: GID-TA11500 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    Discontinued Reference number: GID-TA11277

    Technology appraisal guidance
    Discontinued

  11. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Discontinued Reference number: GID-TA11486

    Technology appraisal guidance
    Discontinued

  12. Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]

    Discontinued Reference number: GID-TA10663

    Technology appraisal guidance
    Discontinued

  13. Pelareorep for untreated pancreatic cancer [ID1074]

    Discontinued Reference number: GID-TA10689

    Technology appraisal guidance
    Discontinued

  14. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued Reference number: GID-TA10836

    Technology appraisal guidance
    Discontinued

  15. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development Reference number: GID-TA10935 Expected publication date: TBC

    Technology appraisal guidance
    In development